TY - JOUR T1 - SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron JF - medRxiv DO - 10.1101/2021.09.08.21263095 SP - 2021.09.08.21263095 AU - Matthew T Laurie AU - Jamin Liu AU - Sara Sunshine AU - James Peng AU - Douglas Black AU - Anthea M Mitchell AU - Sabrina A Mann AU - Genay Pilarowski AU - Kelsey C Zorn AU - Luis Rubio AU - Sara Bravo AU - Carina Marquez AU - Joseph J Sabatino, Jr. AU - Kristen Mittl AU - Maya Petersen AU - Diane Havlir AU - Joseph DeRisi Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/22/2021.09.08.21263095.abstract N2 - The wide spectrum of SARS-CoV-2 variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of the immune response to different spike protein versions. Here, we compare the neutralization of variants of concern, including B.1.617.2 (Delta) and B.1.1.529 (Omicron) in sera from individuals exposed to variant infection, vaccination, or both. We demonstrate that neutralizing antibody responses are strongest against variants sharing certain spike mutations with the immunizing exposure. We also observe that exposure to multiple spike variants increases the breadth of variant cross-neutralization. These findings contribute to understanding relationships between exposures and antibody responses and may inform booster vaccination strategies.SUMMARY This study characterizes neutralization of eight different SARS-CoV-2 variants, including Delta and Omicron, with respect to nine different prior exposures, including vaccination, booster, and infections with Delta, Epsilon, and others. Different exposures were found to confer substantially differing neutralization specificity.Competing Interest StatementDr. DeRisi is a member of the scientific advisory board of The Public Health Company, Inc., and is scientific advisor for Allen & Co. Dr. DeRisi also reports options granted for service on the Scientific Advisory Board of The Public Health Company. None of the other authors have any potential conflicts.Funding StatementThis work was supported by the University of California San Francisco COVID fund [to J.D., M.L., J.L., and S.S.]; the National Institutes of Health [grant number UM1AI069496 to D.H.; and grant number F31AI150007 to S.S.]; the Chan Zuckerberg Biohub [to J.D. and D.H.]; and the Chan Zuckerberg Initiative [to J.D. and D.H.].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCSF Committee on Human Research determined that the study met criteria for public health surveillance. All participants provided informed consent for COVID-19 testing, viral sequencing, and serum collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant viral genome sequences have been deposited in GISAID. https://www.gisaid.org ER -